Evidence map›Paper›PMID 27631228›Full record

SynthesisMedicine2016

Prognostic significance of low microRNA-218 expression in patients with different types of cancer: Evidence from published studies.

Fujiao Duan, Kaijuan Wang, Liping Dai, Xia Zhao, Yajing Feng, Chunhua Song, Shuli Cui, Chengzeng Wang

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fujiao DuanDepartment of Hospital Infection Management Department of Ultrasound, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China Department of Epidemiology, College of Public Health, Zhengzhou University Department of Nosocomial Infection Management, The First Affiliated Hospital of Zhengzhou University Henan Key Laboratory of Tumor Epidemiology, Zhengzhou, Henan, China College of Professional Study, Northeastern University, Boston, MA.
Kaijuan Wang
Liping Dai
Xia Zhao
Yajing Feng
Chunhua Song
Shuli Cui
Chengzeng Wang

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMounting evidence showed that microRNAs may be useful as prognostic biomarkers of cancer. Therefore, we summarize the predictive role of microRNA-218 (miR-218) for survival in patients with various cancers.

methodsWe performed a systematic literature review and assessed the quality of included studies based on Meta-analysis of Observational Studies in Epidemiology group (MOOSE). Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the correlation between miR-218 expression and prognosis of different cancers.

resultsWe identified 10 studies for pooled analyses. For overall survival, a lower expression levels of miR-218 significantly predicted poorer survival, with the pooled HR of 2.61 (95% CI: 2.11-3.22, P < 0.001). For disease-free survival/progressive-free survival/recurrence-free survival (DFS/PFS/RFS), a lower expression level of miR-218 significantly predicted worse DFS/PFS/RFS in various carcinomas, with the pooled HR of 2.73 (95% CI: 2.08-3.58, P < 0.001). Similarly, subgroup analysis by detection method, ethnicity and cancer subtype analysis suggested that lower expression of miR-218 correlated with.

conclusionOur data demonstrated that lower miR-218 expression is significantly associated with poorer overall survival (OS) and DFS/PFS/RFS and may be a novel prognostic biomarker in some cancer types.

Indexed as

Biomarkers, TumorHumansMicroRNAsNeoplasmsPrognosisBiomarkers, TumorMicroRNAsMIRN218 microRNA, human

Identifiers

PMID27631228
PMCPMC5402571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.